Literature DB >> 17760810

Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells.

Teru Hideshima1, Laurence Catley, Noopur Raje, Dharminder Chauhan, Klaus Podar, Constantine Mitsiades, Yu-Tzu Tai, Sonia Vallet, Tanyel Kiziltepe, Enrique Ocio, Hiroshi Ikeda, Yutaka Okawa, Hiromasa Hideshima, Nikhil C Munshi, Hiroshi Yasui, Paul G Richardson, Kenneth C Anderson.   

Abstract

Akt mediates growth and drug resistance in multiple myeloma (MM) cells in the bone marrow (BM) microenvironment. We have shown that a novel Akt inhibitor Perifosine induces significant cytotoxicity in MM cells in the BM milieu. This study further delineated molecular mechanisms whereby Perifosine triggered cytotoxicity in MM cells. Neither the intensity of Jun NH(2)-terminal kinase phosphorylation nor caspase/poly (ADP-ribose) polymerase cleavage correlated with Perifosine-induced cytotoxicity in MM.1S, INA6, OPM1 and OPM2 MM cells. However, survivin, which regulates caspase-3 activity, was markedly downregulated by Perifosine treatment, without changes in other anti-apoptotic proteins. Downregulation of survivin by siRNA significantly inhibited OPM1 MM cell growth, confirming that survivin mediates MM cell survival. Perifosine significantly downregulated both function and protein expression of beta-catenin. Co-culture with BM stromal cells (BMSCs) upregulated both beta-catenin and survivin expression in MM cells, which was blocked by Perifosine. Importantly, Perifosine treatment also downregulated survivin expression in human MM cells grown in vivo in a severe combined immunodeficient mouse xenograft model. Finally, Perifosine inhibited bortezomib-induced upregulation of survivin, associated with enhanced cytotoxicity of combined bortezomib and Perifosine treatment. These preclinical studies provide the framework for clinical trials of bortezomib with Perifosine to improve patient outcome in MM.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17760810     DOI: 10.1111/j.1365-2141.2007.06714.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  43 in total

1.  In vitro effects of perifosine, bortezomib and lenalidomide against hematopoietic progenitor cells from healthy donors.

Authors:  Martin Schmidt-Hieber; Robert Dabrowski; Babette Aicher; Philipp Lohneis; Antonia Busse; Carola Tietze-Buerger; Birgit Reufi; Eckhard Thiel; Igor Wolfgang Blau
Journal:  Invest New Drugs       Date:  2011-07-13       Impact factor: 3.850

Review 2.  Perifosine: update on a novel Akt inhibitor.

Authors:  Joell J Gills; Phillip A Dennis
Journal:  Curr Oncol Rep       Date:  2009-03       Impact factor: 5.075

3.  Cytoplasmic localization of wild-type survivin is associated with constitutive activation of the PI3K/Akt signaling pathway and represents a favorable prognostic factor in patients with acute myeloid leukemia.

Authors:  Juana Serrano-López; Josefina Serrano; Vianihuini Figueroa; Antonio Torres-Gomez; Salvador Tabares; Javier Casaño; Noemi Fernandez-Escalada; Joaquín Sánchez-Garcia
Journal:  Haematologica       Date:  2013-06-28       Impact factor: 9.941

Review 4.  PI3K and Akt as molecular targets for cancer therapy: current clinical outcomes.

Authors:  Ipsita Pal; Mahitosh Mandal
Journal:  Acta Pharmacol Sin       Date:  2012-09-17       Impact factor: 6.150

5.  Targeting MUC1-C is synergistic with bortezomib in downregulating TIGAR and inducing ROS-mediated myeloma cell death.

Authors:  Li Yin; Turner Kufe; David Avigan; Donald Kufe
Journal:  Blood       Date:  2014-03-14       Impact factor: 22.113

6.  Bortezomib-based chemotherapy regimens can improve response in newly diagnosed multiple myeloma patients with bcl-2 and survivin overexpression.

Authors:  Wen Zeng; Fankai Meng; Zeming Liu; Xia Mao; Li Luo; Miao Zheng; Shuang Qin; Wenli Liu; Jianfeng Zhou; Hanying Sun; Lifang Huang
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

Review 7.  Preclinical studies of novel targeted therapies.

Authors:  Teru Hideshima; Kenneth C Anderson
Journal:  Hematol Oncol Clin North Am       Date:  2007-12       Impact factor: 3.722

8.  Glioma is formed by active Akt1 alone and promoted by active Rac1 in transgenic zebrafish.

Authors:  In Hye Jung; Ga Lam Leem; Dawoon E Jung; Min Hee Kim; Eun Young Kim; Se Hoon Kim; Hae-Chul Park; Seung Woo Park
Journal:  Neuro Oncol       Date:  2013-01-16       Impact factor: 12.300

9.  Biologic sequelae of I{kappa}B kinase (IKK) inhibition in multiple myeloma: therapeutic implications.

Authors:  Teru Hideshima; Dharminder Chauhan; Tanyel Kiziltepe; Hiroshi Ikeda; Yutaka Okawa; Klaus Podar; Noopur Raje; Alexei Protopopov; Nikhil C Munshi; Paul G Richardson; Ruben D Carrasco; Kenneth C Anderson
Journal:  Blood       Date:  2009-03-06       Impact factor: 22.113

Review 10.  Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib.

Authors:  Constantine S Mitsiades; Teru Hideshima; Dharminder Chauhan; Douglas W McMillin; Steffen Klippel; Jacob P Laubach; Nikhil C Munshi; Kenneth C Anderson; Paul G Richardson
Journal:  Semin Hematol       Date:  2009-04       Impact factor: 3.851

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.